• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

心脏生物标志物与慢性肾脏病患者心房颤动风险:CRIC 研究。

Cardiac Biomarkers and Risk of Atrial Fibrillation in Chronic Kidney Disease: The CRIC Study.

机构信息

Kidney Research Institute Department of Medicine University of Washington Seattle WA.

Division of Cardiology Department of Medicine University of Washington Seattle WA.

出版信息

J Am Heart Assoc. 2019 Aug 6;8(15):e012200. doi: 10.1161/JAHA.119.012200. Epub 2019 Aug 5.

DOI:10.1161/JAHA.119.012200
PMID:31379242
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6761652/
Abstract

Background We tested associations of cardiac biomarkers of myocardial stretch, injury, inflammation, and fibrosis with the risk of incident atrial fibrillation (AF) in a prospective study of chronic kidney disease patients. Methods and Results The study sample was 3053 participants with chronic kidney disease in the multicenter CRIC (Chronic Renal Insufficiency Cohort) study who were not identified as having AF at baseline. Cardiac biomarkers, measured at baseline, were NT-proBNP (N-terminal pro-B-type natriuretic peptide), high-sensitivity troponin T, galectin-3, growth differentiation factor-15, and soluble ST-2. Incident AF ("AF event") was defined as a hospitalization for AF. During a median follow-up of 8 years, 279 (9%) participants developed a new AF event. In adjusted models, higher baseline log-transformed NT-proBNP (N-terminal pro-B-type natriuretic peptide) was associated with incident AF (adjusted hazard ratio [HR] per SD higher concentration: 2.11; 95% CI, 1.75, 2.55), as was log-high-sensitivity troponin T (HR 1.42; 95% CI, 1.20, 1.68). These associations showed a dose-response relationship in categorical analyses. Although log-soluble ST-2 was associated with AF risk in continuous models (HR per SD higher concentration 1.35; 95% CI, 1.16, 1.58), this association was not consistent in categorical analyses. Log-galectin-3 (HR 1.05; 95% CI, 0.91, 1.22) and log-growth differentiation factor-15 (HR 1.16; 95% CI, 0.96, 1.40) were not significantly associated with incident AF. Conclusions We found strong associations between higher NT-proBNP (N-terminal pro-B-type natriuretic peptide) and high-sensitivity troponin T concentrations, and the risk of incident AF in a large cohort of participants with chronic kidney disease. Increased atrial myocardial stretch and myocardial cell injury may be implicated in the high burden of AF in patients with chronic kidney disease.

摘要

背景

我们在一项针对慢性肾脏病患者的前瞻性研究中,检测了心肌拉伸、损伤、炎症和纤维化的心脏生物标志物与新发心房颤动(AF)风险之间的关联。

方法和结果

研究样本为 CRIC(慢性肾功能不全队列)研究中的 3053 名慢性肾脏病患者,他们在基线时未被诊断为 AF。基线时测量的心脏生物标志物包括 NT-proBNP(氨基末端 B 型利钠肽前体)、高敏肌钙蛋白 T、半乳糖凝集素-3、生长分化因子-15 和可溶性 ST-2。新发 AF(“AF 事件”)定义为 AF 住院。在中位随访 8 年后,279(9%)名参与者发生新的 AF 事件。在调整后的模型中,较高的基线 log 转化 NT-proBNP(氨基末端 B 型利钠肽前体)与新发 AF 相关(每增加一个标准差的调整后 HR:2.11;95%CI,1.75,2.55),log 高敏肌钙蛋白 T 也是如此(HR 1.42;95%CI,1.20,1.68)。在分类分析中,这些关联呈剂量-反应关系。尽管可溶性 ST-2 在连续模型中与 AF 风险相关(每增加一个标准差的 HR:1.35;95%CI,1.16,1.58),但在分类分析中并不一致。log 半乳糖凝集素-3(HR 1.05;95%CI,0.91,1.22)和 log 生长分化因子-15(HR 1.16;95%CI,0.96,1.40)与新发 AF 无显著相关性。

结论

在一个大型慢性肾脏病患者队列中,我们发现较高的 NT-proBNP(氨基末端 B 型利钠肽前体)和高敏肌钙蛋白 T 浓度与新发 AF 风险之间存在很强的关联。增加的心房心肌拉伸和心肌细胞损伤可能与慢性肾脏病患者 AF 负担增加有关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/860f/6761652/6464178edc84/JAH3-8-e012200-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/860f/6761652/6464178edc84/JAH3-8-e012200-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/860f/6761652/6464178edc84/JAH3-8-e012200-g001.jpg

相似文献

1
Cardiac Biomarkers and Risk of Atrial Fibrillation in Chronic Kidney Disease: The CRIC Study.心脏生物标志物与慢性肾脏病患者心房颤动风险:CRIC 研究。
J Am Heart Assoc. 2019 Aug 6;8(15):e012200. doi: 10.1161/JAHA.119.012200. Epub 2019 Aug 5.
2
Change in Cardiac Biomarkers and Risk of Incident Heart Failure and Atrial Fibrillation in CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study.心脏生物标志物变化与慢性肾脏病患者心力衰竭和心房颤动事件风险:慢性肾功能不全队列(CRIC)研究。
Am J Kidney Dis. 2021 Jun;77(6):907-919. doi: 10.1053/j.ajkd.2020.09.021. Epub 2020 Dec 9.
3
Cardiac Biomarkers and Risk of Incident Heart Failure in Chronic Kidney Disease: The CRIC (Chronic Renal Insufficiency Cohort) Study.心脏生物标志物与慢性肾脏病患者心力衰竭事件风险:CRIC(慢性肾功能不全队列)研究。
J Am Heart Assoc. 2019 Nov 5;8(21):e012336. doi: 10.1161/JAHA.119.012336. Epub 2019 Oct 24.
4
Prediction of Incident Atrial Fibrillation in Chronic Kidney Disease: The Chronic Renal Insufficiency Cohort Study.慢性肾脏病患者中房颤事件的预测:慢性肾功能不全队列研究。
Clin J Am Soc Nephrol. 2021 Jul;16(7):1015-1024. doi: 10.2215/CJN.01060121. Epub 2021 Jul 12.
5
Supraventricular arrhythmia, N-terminal pro-brain natriuretic peptide and troponin T concentration in relation to incidence of atrial fibrillation: a prospective cohort study.与房颤发生率相关的室上性心律失常、N 末端脑利钠肽前体和肌钙蛋白 T 浓度:一项前瞻性队列研究。
BMC Cardiovasc Disord. 2021 Mar 12;21(1):134. doi: 10.1186/s12872-021-01942-6.
6
Association of N-terminal pro B-type natriuretic peptide (NT-proBNP) change with the risk of atrial fibrillation in the ARIC cohort.N 末端 pro B 型利钠肽原(NT-proBNP)变化与 ARIC 队列中心房颤动风险的关系。
Am Heart J. 2018 Oct;204:119-127. doi: 10.1016/j.ahj.2018.07.008. Epub 2018 Aug 10.
7
High-sensitivity troponin and the risk of atrial fibrillation in chronic kidney disease: Results from the Chronic Renal Insufficiency Cohort Study.高敏肌钙蛋白与慢性肾脏病患者心房颤动风险:来自慢性肾功能不全队列研究的结果。
Heart Rhythm. 2020 Feb;17(2):190-194. doi: 10.1016/j.hrthm.2019.08.015. Epub 2019 Aug 14.
8
Association of Cardiac Biomarkers With the Kansas City Cardiomyopathy Questionnaire in Patients With Chronic Kidney Disease Without Heart Failure.慢性肾脏病且无心力衰竭患者中心脏生物标志物与堪萨斯城心肌病问卷的相关性。
J Am Heart Assoc. 2020 Jul 7;9(13):e014385. doi: 10.1161/JAHA.119.014385. Epub 2020 Jun 24.
9
Chronic kidney disease and risk of atrial fibrillation and heart failure in general population-based cohorts: the BiomarCaRE project.基于一般人群队列的慢性肾脏病与心房颤动和心力衰竭风险:BiomarCaRE 项目。
ESC Heart Fail. 2022 Feb;9(1):57-65. doi: 10.1002/ehf2.13699. Epub 2021 Nov 26.
10
NT-proBNP is a powerful predictor for incident atrial fibrillation - Validation of a multimarker approach.N末端B型利钠肽原是新发房颤的有力预测指标——多标志物方法的验证
Int J Cardiol. 2016 Nov 15;223:74-81. doi: 10.1016/j.ijcard.2016.08.001. Epub 2016 Aug 4.

引用本文的文献

1
Cardiac Troponins in Kidney Disease.肾病中的心肌肌钙蛋白
Eur Cardiol. 2025 Aug 13;20:e22. doi: 10.15420/ecr.2024.51. eCollection 2025.
2
The Dual Burden: Exploring Cardiovascular Complications in Chronic Kidney Disease.双重负担:探索慢性肾脏病中的心血管并发症。
Biomolecules. 2024 Oct 31;14(11):1393. doi: 10.3390/biom14111393.
3
Soluble ST2 for predicting heart failure, atrial fibrillation and death in patients with coronary heart disease with or without renal insufficiency.可溶性ST2用于预测伴或不伴肾功能不全的冠心病患者发生心力衰竭、心房颤动及死亡的情况。

本文引用的文献

1
Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association.心脏肾脏综合征:分类、病理生理学、诊断和治疗策略:美国心脏协会的科学声明。
Circulation. 2019 Apr 16;139(16):e840-e878. doi: 10.1161/CIR.0000000000000664.
2
Cardiovascular Events after New-Onset Atrial Fibrillation in Adults with CKD: Results from the Chronic Renal Insufficiency Cohort (CRIC) Study.慢性肾脏病患者新发心房颤动后的心血管事件:慢性肾功能不全队列(CRIC)研究结果。
J Am Soc Nephrol. 2018 Dec;29(12):2859-2869. doi: 10.1681/ASN.2018050514. Epub 2018 Oct 30.
3
Heliyon. 2024 Apr 20;10(9):e29804. doi: 10.1016/j.heliyon.2024.e29804. eCollection 2024 May 15.
4
Association of soluble suppression of tumorigenicity 2 with mortality and adverse outcomes in chronic kidney disease: a systematic review and meta-analysis.可溶性肿瘤抑制因子 2 与慢性肾脏病患者死亡率及不良预后的相关性:系统评价和荟萃分析。
Clin Exp Nephrol. 2024 Oct;28(10):988-1003. doi: 10.1007/s10157-024-02506-6. Epub 2024 Apr 27.
5
Predictive value of soluble suppression of tumorigenicity 2 in atrial fibrillation: a systematic review and meta-analysis.可溶性肿瘤形成抑制因子2在心房颤动中的预测价值:一项系统评价和荟萃分析
Front Cardiovasc Med. 2024 Jan 11;10:1308166. doi: 10.3389/fcvm.2023.1308166. eCollection 2023.
6
Insights into the Role of Galectin-3 as a Diagnostic and Prognostic Biomarker of Atrial Fibrillation.探讨半乳糖凝集素-3在心房颤动诊断和预后中的作用。
Dis Markers. 2023 Oct 9;2023:2097012. doi: 10.1155/2023/2097012. eCollection 2023.
7
Associations of Apixaban Dose With Safety and Effectiveness Outcomes in Patients With Atrial Fibrillation and Severe Chronic Kidney Disease.阿哌沙班剂量与伴有严重慢性肾脏病的心房颤动患者安全性和有效性结局的相关性。
Circulation. 2023 Nov 7;148(19):1445-1454. doi: 10.1161/CIRCULATIONAHA.123.065614. Epub 2023 Sep 8.
8
Cardiac Biomarkers and Risk of Atherosclerotic Cardiovascular Disease in Patients with CKD.心脏生物标志物与慢性肾脏病患者动脉粥样硬化性心血管疾病风险
Kidney360. 2022 Mar 2;3(5):859-871. doi: 10.34067/KID.0006222021. eCollection 2022 May 26.
9
Relationship between serum growth differentiation factor 15, fibroblast growth factor-23 and risk of atrial fibrillation: A systematic review and meta-analysis.血清生长分化因子15、成纤维细胞生长因子-23与心房颤动风险的关系:一项系统评价和荟萃分析。
Front Cardiovasc Med. 2022 Aug 4;9:899667. doi: 10.3389/fcvm.2022.899667. eCollection 2022.
10
Research Progress of Myocardial Fibrosis and Atrial Fibrillation.心肌纤维化与心房颤动的研究进展
Front Cardiovasc Med. 2022 Jul 25;9:889706. doi: 10.3389/fcvm.2022.889706. eCollection 2022.
Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF.
射血分数保留的心力衰竭中冠状动脉微血管功能障碍的患病率及其相关因素:PROMIS-HFpEF。
Eur Heart J. 2018 Oct 1;39(37):3439-3450. doi: 10.1093/eurheartj/ehy531.
4
Myocardial Injury and Cardiac Reserve in Patients With Heart Failure and Preserved Ejection Fraction.心力衰竭伴射血分数保留患者的心肌损伤和心脏储备。
J Am Coll Cardiol. 2018 Jul 3;72(1):29-40. doi: 10.1016/j.jacc.2018.04.039.
5
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.恩格列净如何降低心血管死亡率?来自 EMPA-REG OUTCOME 试验中介分析的见解。
Diabetes Care. 2018 Feb;41(2):356-363. doi: 10.2337/dc17-1096. Epub 2017 Dec 4.
6
Galectin-3 and incidence of atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study.半乳糖凝集素-3与心房颤动发病率:社区动脉粥样硬化风险(ARIC)研究
Am Heart J. 2017 Oct;192:19-25. doi: 10.1016/j.ahj.2017.07.001. Epub 2017 Jul 8.
7
Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes.卡格列净对 2 型糖尿病老年患者心血管生物标志物的影响。
J Am Coll Cardiol. 2017 Aug 8;70(6):704-712. doi: 10.1016/j.jacc.2017.06.016. Epub 2017 Jun 12.
8
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.卡格列净与 2 型糖尿病的心血管和肾脏事件。
N Engl J Med. 2017 Aug 17;377(7):644-657. doi: 10.1056/NEJMoa1611925. Epub 2017 Jun 12.
9
Association of Fibroblast Growth Factor 23 With Atrial Fibrillation in Chronic Kidney Disease, From the Chronic Renal Insufficiency Cohort Study.成纤维细胞生长因子 23 与慢性肾脏病心房颤动的关系:来自慢性肾功能不全队列研究。
JAMA Cardiol. 2016 Aug 1;1(5):548-56. doi: 10.1001/jamacardio.2016.1445.
10
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.恩格列净:在 2 型糖尿病中的心血管结局和死亡率。
N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17.